Fosun Pharmaceutical

Inverse H&S in pharma index could revive a positive bias for short-term

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Fosun reportedly planning sale of India's $3.6 billion Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland

We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Stocks to watch: HDFC, Sun Pharma, Dr Reddy's, STFC, TVS Motor, SpiceJet

Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Rejuvenating Cipla: After global expansion, acquisitions on cards

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Netherlands jumps 5 places to become India's 5th-largest export destination

Germany, which was earlier India's top European export destination (eighth position), has now dropped two ranks to 10th place

Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

Sun Pharma rallies 8% in 2 days on heavy volumes; stock nears 52-week high

Sun Pharma announced that its subsidiary Taro Pharmaceuticals USA Inc has completed the acquisition of subsidiary companies of Galderma

Sun Pharma expected to shine on domestic prospects, US sales ramp up

Anti-covid drug approval, new facility are the near term triggers for the pharma firm's stock

Prices of oral diabetes drugs set to fall as patents near expiry date

The diabetes segment has been growing faster than the country's overall drug market

Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 bn

Fosun Pharma and Fosun International said following the completion of the acquisition, Gland Pharma has become an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International

China's Fosun to buy 74% stake in Gland Pharma for $1.1 bn in revised deal

India allows foreign investment of up to 100% in pharmaceutical sector but above 74% requires govt approval

Fosun Pharma to buy 74% stake in Gland for $1.09 billion

Agrees to cut size of stake in Hyderabad-based injectable maker to 74%, after earlier proposal to acquire 86% met approval roadblock